Spaniol K, Holtmann C, Geerling G, Schrader S
Augenklinik, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Ophthalmologe. 2017 Apr;114(4):307-317. doi: 10.1007/s00347-016-0419-1.
Reconstruction of the conjunctiva is an essential part of ocular surface reconstruction. Clinically applied and experimentally tested tissue- and stem-cell-based approaches are presented and evaluated.
Current literature and our own results will be presented.
Autologous conjunctiva, mucous membrane of the mouth or nose, and amniotic membrane are routinely used for conjunctival reconstruction. Limitations are limited availability, involvement in autoimmune diseases, donor heterogeneity, and degradation in an inflamed environment. Experimentally tested matrices as tissues made from extracellular matrix proteins, synthetic polymers, temperature-sensitive culture dishes, and decellularized conjunctiva have been tested in vitro and partly in vivo. To replace conjunctival cells, cells of conjunctiva and mucous membrane of mouth and nose have been evaluated and show progenitor cell properties as well as secretory capacity (goblet cell differentiation).
Although different matrices are available for conjunctival reconstruction there is-due to specific limitations of existing tissues-a need for the development of new therapies for conjunctival replacement. Matrices produced in the laboratory have already been partly investigated in vivo and may thus be clinically applicable in the near future. Adult mucous membrane cells show many properties of conjunctival epithelium after expansion in vitro and thus are a promising cell source for conjunctival tissue engineering. Other stem cells sources require further evaluation.
结膜重建是眼表重建的重要组成部分。本文介绍并评估了临床应用和实验测试的基于组织和干细胞的方法。
将展示当前的文献及我们自己的研究结果。
自体结膜、口腔或鼻腔黏膜以及羊膜常用于结膜重建。其局限性在于可用性有限、与自身免疫性疾病有关、供体异质性以及在炎症环境中会降解。经过实验测试的基质,如由细胞外基质蛋白制成的组织、合成聚合物、温度敏感培养皿和脱细胞结膜,已在体外进行了测试,部分也在体内进行了测试。为替代结膜细胞,已对结膜以及口腔和鼻腔黏膜的细胞进行了评估,这些细胞显示出祖细胞特性以及分泌能力(杯状细胞分化)。
尽管有不同的基质可用于结膜重建,但由于现有组织的特定局限性,仍需要开发新的结膜替代疗法。实验室生产的基质已在体内进行了部分研究,因此可能在不久的将来应用于临床。成年黏膜细胞在体外扩增后显示出结膜上皮的许多特性,因此是结膜组织工程有前景的细胞来源。其他干细胞来源需要进一步评估。